Risultati per: Artrosi dell’anca. Approccio infltrativo ecoguidato con acido ialuronico: evidenze cliniche

Attraverso l’embolizzazione delle arterie genicolari

Delicato intervento all’ospedale Cardarelli di Campobasso

Rarissimo caso di severa osteoporosi transitoria in gravidanza

L’high-tech dei container medici d’emergenza apprezzati dal Papa

L’high-tech dei container medici d’emergenza apprezzati dal Papa

Iniziativa benefica high-tech mercoledì in Vaticano

Primi due interventi di “mininvasiva” all’ospedale di Urbino

Introduction
Relapses in ANCA-associated vasculitis (AAV) increase the incidence of end-organ damage and their prevention requires prolonged immunosuppressive therapy. Rituximab, a type I anti-CD20 B cell depleting monoclonal antibody, is the current standard of care for induction of disease remission. Rituximab is not always effective and is associated with a high subsequent relapse risk. Obinutuzumab is a type II anti-CD20 humanised monoclonal antibody with the potential to obtain greater tissue B cell depletion than rituximab and reduce relapse risk in AAV.

Methods and analysis
ObiVas is a randomised, phase II, double-blind controlled trial that will compare the mechanistic effects of rituximab and obinutuzumab in the induction treatment of patients with AAV positive for proteinase 3 ANCA (PR3-ANCA). 26 patients, either newly diagnosed or relapsing, will be recruited from a single centre and randomised in a 1:1 ratio to receive 1000 mg rituximab or obinutuzumab as induction therapy on days 1 and 15, alongside a tapering glucocorticoid regimen. The primary end point is CD19+ B cell depletion in nasal-associated lymphoid tissue (NALT), assessed as change from baseline to week 26. Secondary outcomes will compare the safety and clinical efficacy of rituximab and obinutuzumab and their impact on immune biomarkers, including tissue and peripheral blood lymphocyte subsets and PR3-ANCA binding levels. Patients are followed through to week 78. The trial opened for recruitment in January 2023 and is forecasted to complete recruitment by the end of 2024.

Ethics and dissemination
For all patients, informed written consent will be obtained in keeping with Good Clinical Practice. Trial results will be disseminated to the relevant scientific, clinical and patient communities on trial closure. NALT data analysis will start before trial completion. Other analyses will be reported after trial completion. This trial was given ethical approval by Edgbaston (West Midlands) Research Ethics Committee (approval reference 22/WM/0174).

Trial registration number
ISRCTN13069630.

Già oggi ne mancano almeno 65-70mila, ma nei prossimi anni con il maxi esodo dei pensionamenti ne mancheranno ancora di più

Test efficacia molecole su campioni tessuto quasi in tempo reale